![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 280, Issue 3, 1374-1382, 1997
Addiction Research Foundation, 33 Russell Street, Toronto, Ontario, M5S 2S1 (D.M.T., S.V.O., N.J., N.Y.L., R.F.T., E.M.S.) and Departments of Pharmacology, Medicine and Psychiatry, University of Toronto, Toronto, Ontario, Canada (R.F.T., E.M.S.) and Center for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia (R.B.)
 |
Abstract |
|---|
 Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
Humans that lack cytochrome P450 2D6 (CYP2D6) activity may have an altered risk of drug dependence or abuse because this enzyme is important in the metabolism of some drugs of abuse, including hydrocodone. In rats, hydrocodone conversion to hydromorphone is catalyzed by CYP2D1, the rat homolog of the human CYP2D6. To determine the impact of impaired hydromorphone formation on the behavioral effects of the parent compound, hydrocodone-induced analgesia and hyperactivity, hydrocodone discrimination and self-administration were examined in male Wistar rats, with or without pretreatment with CYP2D1 inhibitors (quinine and budipine). In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) produced a marked suppression in brain and plasma hydromorphone levels detected after the peripheral administration of hydrocodone, thus confirming that the doses used suppressed CYP2D1 activity. In contrast, CYP2D1 inhibition had no impact on the analgesic or discriminative stimulus effects of hydrocodone, nor did this type of manipulation alter hydrocodone self-administration. The effects of quinine on the locomotor activating effects of hydrocodone were subtle at best. Because inhibition of CYP2D1 in this rat strain is proposed to be a useful animal counterpart for studying the impact of CYP2D6 polymorphism in humans, these data suggest that differences in CYP2D6 phenotype will have limited influence on the drug response to hydrocodone after nonoral administration. This has recently been verified in a study showing that inhibition of hydrocodone biotransformation to hydromorphone does not affect measures of abuse liability. Therefore, hydrocodone's behavioral effects are most likely attributable to its own intrinsic effects at mu opioid receptors.
| |
Introduction |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
HC (dihydrocodeinone) is a
semisynthetic opioid related structurally to codeine. It is used
therapeutically as an antitussive agent, and is only available on
prescription. The addictive liability of HC seems more comparable to
morphine, than to codeine. HC is similar to morphine in inducing
euphoria in former morphine addicts, and completely relieves the signs
of morphine abstinence (Fraser and Isbell, 1950
). Other studies in
postaddicts also indicated that single doses of HC and morphine are
approximately equipotent (Jasinski and Martin, 1967). As with codeine
(Yue et al., 1989; Chen et al., 1991), HC is
metabolized by the genetically variable drug metabolizing enzyme,
cytochrome P450 2D6 (CYP2D6) (Otton et al., 1993). The
product of this reaction is HM. HM itself is marketed as Dilaudid and
used in the management of severe pain. When administered s.c., the
analgesic potency of HM is seven to eight times greater than that of
morphine (Jaffe et al., 1990), and it has been shown
experimentally to be seven times more potent than morphine in
suppressing morphine abstinence (Himmelsbach, 1941). Not surprisingly,
HM has powerful mood-enhancing properties (Preston et al.,
1989) and it produces similar discriminative stimulus effects to those
elicited by other abused opioids, e.g., morphine (Jasinski,
1977).
Based on binding studies using rat tissues, the question has been
raised whether HC depends on metabolic conversion to HM for its opiate
effects. Chen et al. (1991) observed that HM was 33 times
more potent than HC in displacing 3H-DAMGO, a highly
specific µ-receptor ligand, in homogenates of rat whole brain less
cerebellum. Earlier, Hennies et al. (1988) had compared the
IC50 of HC and HM against 3H-dihydromorphine
(µ-receptor ligand) and 3H-ethylketocyclazocine
(kappa receptor ligand) in rat whole brain homogenates. HM
was 7 times more potent than HC at the mu receptor and 37 times more potent at the kappa receptor. These authors (Hennies et al., 1988) also compared HC and HM using tail
flick analgesia to radiant heat. They found parallel dose-response
curves, with HM being more than four times more potent than HC
(ED50 = 0.28 mg/kg and 1.18 mg/kg, respectively). Even
greater (20-200 times) differences in analgesic potency were observed
by Plummer et al. (1990) after intrathecal administration
using hot plate and tail flick tests. Because HM exhibits greater
potency in these assays than HC, it is plausible that the HM formed
after HC administration contributes significantly to the overall
pharmacological effects observed.
The enzyme that mediates the formation of HM from HC (CYP2D6) is absent
in approximately 7% of Caucasians as a result of inherited mutations
in the CYP2D6 gene (for recent review, see Kroemer and Eichelbaum,
1995). As a result, the pharmacokinetics of formed HM is profoundly
different in these people (PM) compared to the rest of the population
(EM). We (Otton et al., 1993) observed that the partial
metabolic clearance to HM after a 10 mg oral HC bitartrate was 725%
faster in EM than in PM (28.1 + 10.3 vs. 3.4 + 2.4 ml/hr/kg). Furthermore, pretreatment of EM with quinidine (a selective
inhibitor of CYP2D6 activity) on another occasion reduced their
clearance to levels similar to that seen in PM. HM Cmax was
445% higher in EM than PM and in EM when pretreated with quinidine. In
this study, subjective and physiologic measures were taken
coincidentally with blood sampling over the first 2 hr postdosing. No
statistically significant differences in physiologic measures were
observed. However, during the first hour after dosing, EM reported more
positive opiate effects and fewer unpleasant opiate effects compared to
PM, and on the test day when their CYP2D6 activity was inhibited by
quinidine pretreatment (Otton et al., 1993). However, a
larger (n = 25), double-blind, placebo-controlled trial
failed to find any phenotypic differences in the abuse liability of HC
(Kaplan et al., 1996). This finding was surprising in view of other data indicating that PM obtain slightly less analgesia than EM
after codeine, which is metabolized to morphine by CYP2D6 (Yue et
al., 1989; Chen et al., 1991).
Studies in rats (Cleary et al., 1994; Ritchie et
al., 1990) have demonstrated that codeine analgesia (tail flick
test) was related to the extent of codeine converted to morphine. In
rats, this reaction is catalyzed by the rat homolog of human CYP2D6, CYP2D1 (Zysset et al., 1988; Mikus et al., 1990;
Barham et al., 1994). Cleary et al. (1994) showed
that codeine did not produce analgesia in Dark Agouti rats, a strain
deficient in CYP2D1 activity and the animal counterpart of the human PM
phenotype (Al-Dabbagh et al., 1981). Furthermore, codeine
analgesia was attenuated in Sprague-Dawley rats (an EM counterpart) by
pretreatment with 40 mg/kg s.c. quinine, a selective inhibitor of
CYP2D1 activity (Kobayashi et al., 1989).
The only behavioral studies that have specifically compared the effects
of a psychoactive drug in rats with functional and deficient CYP2D1
have used amphetamines. Enhanced stereotypy from amphetamine (Freeman
and Sulser, 1974) and methamphetamine (Suzuki et al., 1984;
1986) have been observed in Sprague-Dawley rats after inhibition of the
4-hydroxylation of these drugs, either by CYP2D1 inhibitors or by other
nonspecific P450 inhibitors. Similarly, we (D. M.Tomkins, unpublished
data) observed that CYP2D1 inhibition was associated with significant
increases in the duration of amphetamine-induced hyperactivity and the
discriminative stimulus effects of amphetamine in Wistar rats (an EM
counterpart). Furthermore, budipine, a novel antiparkinsonian drug
(Jackisch et al., 1993), which potently inhibits CYP2D1
activity in vitro (Ki = 130 nM; D. Wu, unpublished data) suppressed amphetamine self-administration behavior in this rat strain. The behavioral profiles showed good correlation with the effect of CYP2D1 inhibition on the pharmacokinetic profile of amphetamine. In our study, the same strategy has been used
to determine the impact of CYP2D1 inhibition on the analgesic, locomotor activating and discriminative stimulus effects of HC, as well
as HC self-administration behavior. The effects of the CYP2D1
inhibitors, budipine and quinine, on plasma and brain levels of HC and
HM were also examined to confirm that the doses used in the behavioral
studies were sufficient to suppress CYP2D1 activity.
| |
Methods |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
Animals and Housing
Except where stated, subjects were experimentally naive male Wistar rats (Charles River, Quebec, Canada) that were individually housed in a temperature controlled environment (22-44°C) on a 12-hr light/dark cycle. Rats used in the locomotor, analgesia and pharmacokinetic studies were given free access to food and water. Rats used in the drug discrimination and self-administration studies were given free access to water but were maintained on a restricted diet of approximately 16 g of food per day (Lab Diet, Richmond, IN) made available in the home cage after each test session. In addition, the drug discrimination rats could earn up to a maximum of 2.25g of food pellets (dustless precision pellets, Bio-Serv) during the training and test sessions. Before initiating these studies all animals were handled during a 1-wk habituation period to the animal housing facility.
Drugs and Injections
All drug solutions were prepared daily. Doses are expressed as the free base and were administered in a 2 ml/kg volume. HC bitartrate (Du Pont Merck Pharma, Mississauga, Ontario, Canada), HM hydrochloride (Knoll Pharmaceutics, Mount Olive, NJ) and quinine hydrochloride (Sigma Chemical Co., St. Louis, MO) were dissolved in saline. Budipine hydrochloride (Byk Gulden Pharmazeutika, Konstanz, Germany) was administered in a 0.5% methyl cellulose solution.
Experiment 1: Effect of CYP2D1 inhibition on plasma and whole brain levels of HC and HM
Five groups of five rats (body weights of 350-400 g) were injected with either HC (3 mg/kg, s.c.), then killed by decapitation at 30 or 60 min postinjection, or HM (0.5 mg/kg, s.c.) and then killed at 30, 60 or 90 min later. In four other groups, HC administration (3 mg/kg, s.c.) was preceded by either quinine (20 mg/kg, i.p., 60-min pretreatment time) or budipine (10 mg/kg, i.p., 30-min pretreatment time) and the animals were killed either 30 or 60 min later. Trunk blood was collected into heparinized tubes. Plasma was separated by centrifugation (10 min at 3000 rpm) and stored at -20°C until analysis. Immediately after decapitation, whole brains were removed, the cerebellum dissected out, washed with ice-cold saline and homogenized in distilled water (1 g/2 ml). Unchanged HC, and free and total HM (i.e., conjugated plus unconjugated) were assayed using a previously described method (Otton et al., 1993),
except that acetonitrile (4 ml) was used to extract the drugs from
plasma (2 ml) or brain homogenate (2 ml) saturated with sodium
chloride. After the samples were vortexed for 5 min and centrifuged at
3000 rpm for 10 min, the acetonitrile extracts were dried under
nitrogen gas and then the residues were resuspended in acetonitrile
(0.4 ml). The acetonitrile extracts were evaporated to dryness under
nitrogen gas and resuspended in 0.2 ml 0.05% phosphoric acid. An
aliquot was analyzed by high-performance liquid chromatography using
tandem UV detection (for HC and its internal standard, oxycodone) and
electrochemical detection (for HM and its internal standard,
nalorphine). The limit of detection was 1 and 25 ng/ml plasma or g
brain tissue for HM and HC, respectively.
Experiment 2: Effect of CYP2D1 inhibition on HC analgesia
Before the experimental studies, the animals were habituated to the hot plate until stable responding was established following the methodology outlined by Paronis et al. (1993). The test
procedure consisted of placing the rats individually in a plastic cage
with an aluminum floor. The cage was situated in a hot water bath to maintain the plate at 51°C. The latency to hind paw lick or jump was
recorded as the PLL. Immediately after either response was observed or
after 60 sec, whichever occurred first, the animal was removed from the
apparatus. In the first part of the study eight rats were allocated to
one of four treatment sequences such that each animal received all
treatments of HC (0, 6, 8 and 10 mg/kg) using a balanced design. On
test days the rats were given four habituation trials separated by at
least 45 min. Ten min after the final trial the rats received s.c.
injections of either saline or HC (6-10 mg/kg) and were reexposed to
the test apparatus 30 min later. Each test session was separated by at
least 48 hr. For the CYP2D1 inhibition studies, the same animals were
reallocated to one of six treatment sequences (after a 2-wk washout
period) in which quinine (20 mg/kg i.p., 60 min pretreatment) or
budipine (10 mg/kg i.p., 30 min pretreatment) was administered before
the HC injection. For comparative purposes, the effect of the opioid antagonist naloxone (1 mg/kg i.p., 30 min pretreatment) on the analgesic effects of HC was also examined.
Experiment 3: Effect of CYP2D1 inhibition on HC- and HM-induced hyperactivity
Locomotor activity was assessed using clear Plexiglas boxes (40 × 40 × 20 cm), each of which was placed within the arena of an OptoVarimex activity meter (Columbus Instruments, Columbus, OH). Locomotor activity was calculated as either the total number of locomotor counts (first study) that were manually recorded from the activity meters or the distance traveled (cm) within each 20-min sample period and stored on an IBM-compatible computer using the Auto-Track software package (Columbus Instruments) (second study). Distance traveled data were not available for the initial study due to computer malfunction. In the first part of this study, two groups of rats (n = 12/group) were placed individually in the activity boxes for three 3-hr periods on consecutive days to habituate them to the testing procedure. The rats were then allocated to one of five treatment sequences so that the first group received injections of HC (0, 0.1, 0.3, 0.5 and 1 mg/kg s.c.), whereas the second group were injected with HM (0, 0.01, 0.03, 0.05 and 0.1 mg/kg s.c.). Doses were administered using a randomized design such that all animals received all treatments. On test days, the rats were placed in the activity boxes; 1 hr later the allocated drug treatment was administered and then their locomotor activity was automatically recorded for the subsequent 2-hr period. Test sessions were run twice a week and separated by at least 2 days. To assess the effect of CYP2D1 inhibition on the locomotor activating effects of HC and HM, two separate and drug naive groups of rats were habituated to the activity boxes as described above. One group of animals (n = 7) was randomly allocated to one of six test cycles with each cycle lasting for 3 hr and separated by at least 48 hr. On test days, each rat received an injection of either vehicle or quinine (20 mg/kg i.p.) and placed in the activity apparatus. One hour later, each rat received a second injection consisting of either vehicle or 0.5 mg/kg HC and locomotor activity was monitored for another 2 hr. The injection schedule was conducted in a randomized block design such that all rats received each treatment combination. In a parallel study, the second group of rats (n = 8) were similarly treated except that the second injection administered was either vehicle or HM (0.05 mg/kg).Experiment 4: Effect of CYP2D1 inhibition on the discriminative stimulus properties of HC
The first series of discrimination experiments were conducted at the Addiction Research Foundation. The test apparatus consisted of four identical test chambers (22 × 22 × 28 cm, LxWxH; Med Associates Inc., St. Albans, VT) each containing two response levers mounted 7 cm above a grid floor and positioned either side of the pellet dispenser. Reinforcement delivery was controlled by a microcomputer interface (Med Associates) linked to a 386sx IBM computer. The rats were trained in groups of four with each rat always being placed in the same designated test chamber. They were initially trained to lever press for food reinforcement (45-mg dustless precision pellet) under an FR-1 schedule during twice daily sessions, from Monday to Saturday. Each session began immediately after the animal was placed in the test chamber and the signal light was turned on. Drug discrimination training began once stable responding for food was observed following the procedure outlined in Higgins et al. (1994). Rats were given daily discrimination trials, with either
morphine (3 mg/kg s.c.) or saline (2 ml/kg s.c.) injected 30 min before
each session. The rats could obtain food reinforcement by responding
selectively on one of the two levers after morphine or on the
alternative lever after saline administration. To control for
positional preferences, the treatment assigned to a particular lever
was counterbalanced. Responses on the inappropriate lever were recorded
but had no programed consequences. Initially, each response on the
correct lever resulted in the presentation of a food pellet. Once
responding was stable, the number of responses required for each food
pellet was gradually increased to an FR-10 schedule. Once the FR-10
schedule was attained, each animal received only one daily training
session that lasted either 15 min or until the animal had acquired 50 food pellets. Training on this schedule was continued until the
following criteria were met on six consecutive sessions. Animals must
have made no more than 16 lever presses preceding the delivery of the
first reinforcement with 95% of the total responses thereafter on the drug-appropriate lever. During discrimination training, morphine and
saline trials were presented on a fixed 20-day schedule,
i.e., DVVDV, VDVDD, VDDVV, DVDVD (where V = vehicle;
D = morphine).
During the experimental phase of the study, test sessions during which
both levers were active, were conducted on Wednesdays and Saturdays.
Training trials were continued on the intervening days to ensure that
discrimination was maintained. Initially, generalization curves for
different doses of morphine (0, 0.3, 1, 1.5, 3, and 5 mg/kg/2 ml), HM
(0, 0.03, 0.075, 0.1 and 0.2 mg/kg/2 ml) and HC (0, 0.1, 0.3, 1, 2 and
3 mg/kg/2 ml) were established. The ability of HC and HM to substitute
for the morphine training dose was examined at two time points, 30 and
60 min. Finally, the effect of the CYP2D1 inhibitor, budipine (10 mg/kg/2 ml; 30-min pretreatment), on the ability of HC (30-min
pretreatment) to substitute for morphine was examined
(n = 4). All injections in this experiment were given
s.c.
In a second drug discrimination experiment conducted at the Center for
Drug and Alcohol Studies, nine male Sprague-Dawley rats (COBS CD,
Charles River, Wilmington, MA) were trained to discriminate morphine
(2.5 mg/kg i.p., 15-min pretreatment) from saline in a similar manner
to that described above with the exceptions that correct lever
responding was reinforced under an FR-32 schedule and that incorrect
responses reset the FR schedule. Test sessions were carried out once
animals had reached criteria on the preceding Monday or Thursday
training session of the first FR on the correct lever and 85% or more
responding was on the drug appropriate lever for the entire session.
Initially, a morphine generalization curve was established, and then
the ability of HC to substitute was examined at doses ranging from 0.5 to 8 mg/kg i.p. (15-min pretreatment). This was followed by a
redetermination of the HC dose-effect curve, except that the CYP2D1
inhibitor, quinine (20 mg/kg i.p.), was administered to the rats 75 min
before the test session.
Experiment 5: Effect of CYP2D1 inhibition on HC self-administration
Testing was conducted in eight identical operant chambers (22 × 22 × 28 cm, LxWxH; Med Associates Inc.) each containing two response levers mounted 7 cm above a grid floor and positioned either side of the pellet dispenser. Stimulus lights were mounted 5 cm above each lever and a house light was positioned at the back of the chamber. The house light was illuminated throughout the session except during the time-out phase of the self-administration procedure. Reinforcement delivery was controlled by a microcomputer interface (Med Associates) linked to a 386sx IBM computer. These studies were conducted following the procedure outlined in Higgins et al. (1994) and are therefore only briefly summarized
here.
Rats were initially trained to lever press for food reinforcement until
stable responding on an FR-5 schedule was attained. Nine rats were
surgically implanted with an i.v. catheter into the right jugular vein
under acepromazine (10 mg/kg i.p.) and ketamine (100 mg/kg
intramuscularly) anesthesia. The catheter was exteriorized on the back
of the animal between the scapulae. The catheters were infused daily
with 0.1 ml heparinized saline (30 IU/ml) to help maintain patency.
After 7 days recovery, self-administration sessions were begun. The
rats were trained to press a designated lever to receive an infusion of
HC (0.16 mg/kg body weight/infusion) during 60-min test sessions. The
reinforcement conditions were initially set such that one lever press
resulted in a 0.05 ml infusion of HC over a 5-sec period. For a 60-sec
period after each infusion the houselight was switched off and the
levers were inactivated. Any lever presses made during this time were
recorded but not reinforced. When an animal had displayed stable
responding under the FR-1 schedule, the schedule of reinforcement was
gradually increased to FR-5. Drug testing began once rates of self
administration had stabilized at an average of 10 infusions/session.
The effect of CYP2D1 inhibition on HC self administration over a range
of HC drug levels (0.02, 0.04, 0.08, 0.16 and 0.32 mg/kg/infusion) was
then assessed during single daily test session. Budipine (10 mg/kg; 30 min pretreatment), quinine (15 mg/kg; 60 min pretreatment) or saline
was administered before the start of the test session. All animals in
the study received each treatment using a counterbalanced design.
Data Analysis
For the pharmacokinetic study, Student's t tests were used to determine the statistical significance of time and inhibitor pretreatment on the plasma and brain levels of HC and HM. For the locomotor activity experiments, to determine the effect of CYP2D1 inhibition on the time course of HC- and HM-induced hyperactivity a two-way analysis of variance was used, with time and treatment as the main effects. Where appropriate, significant main effects were followed by individual mean comparisons using planned contrasts. For the drug discrimination studies ED50 and confidence limits were calculated using Litchfield-Wilcoxon analysis with the Pharmacological Calculation System software for the IBM computer.
| |
Results |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
Experiment 1: Effect of CYP2D1 Inhibition on Plasma and Brain Levels of HC and HM. After peripheral administration of HC, the HC level in the brain was higher at 30 min, compared to 60 min postinjection (table 1). Furthermore, the brain levels of HC were higher than those seen in the plasma at equivalent time points (table 1). Pretreatment with the CYP2D1 inhibitor, budipine, but not quinine, resulted in a significant elevation in plasma HC levels (table 1). Thirty min post-HC administration, the brain-free HM level was 3.3 ng/g; this level was increased 2-fold at 60 min postinjection (P < .05). Although plasma free HM levels were similar to those in the brain, total plasma HM increased by 14- to 20-fold at 30 and 60 min, respectively (fig. 1).
|
|
|
Experiment 2: Effect of CYP2D1 Inhibition on HC Analgesia.
HC
produced a significant dose dependent antinociceptive effect in the hot
plate test for analgesia (F9.67 = 10.3, P < .001; fig. 2). Pretreatment with neither quinine nor budipine alone produced any significant effects on paw lick latency, nor did they
alter the analgesic effects of HC. In contrast, the opioid antagonist
naloxone, completely abolished the antinociceptive effects of a high
dose (10 mg/kg) of HC (fig. 2).
|
Experiment 3: Effect of CYP2D1 Inhibition on HC- and HM-Induced
Hyperactivity.
The effects of HC and HM on the locomotor activity
in Wistar rats is shown in figure 3. One-way analysis of
variance with repeated measures revealed a significant dose effect for
both HC (F4,44 = 10.2, P < .001) and HM
(F4,44 = 5.6, P < .001). HM was approximately 10-fold
more potent than HC in producing hyperactivity in these animals. From
this study, doses of 0.05 mg/kg HM and 0.5 mg/kg HC were selected for
the CYP2D1 inhibition studies.
|
|
Experiment 4. Effect of CYP2D1 Inhibition on the Discriminative
Stimulus Properties of HC.
The generalization curves for HM and HC
from the 3 mg/kg morphine training dose in male Wistar rats are
presented in figures 5 and 6. In the case
of HM, the discriminative stimulus effects were moderately greater when
the drug was given 60 min before the test session, compared to 30 min
[ED50 values (95% confidence limits) were 0.09 (0.06-0.13) and 0.15 (0.09-0.22) mg/kg, respectively]. In contrast,
the discriminative stimulus effects of HC were similar when the drug
was administered either as a 30 min or 60 min pretreatment (ED50 values [95% confidence limits] for the 30 and 60 min pretreatment times were 0.5 [0.2-1.2] and 0.7 [0.3-1.7]
mg/kg, respectively. HM was approximately 7-fold more potent than HC
and 13 times more potent than morphine [ED50 = 1.3 (0.9-0.8) mg/kg] in these generalization tests. Inhibition of CYP2D1
activity by pretreating the animals with budipine did not decrease the
ability of HC to substitute for morphine, nor alter its response-rate
reducing effects (fig. 6).
|
|
). If anything, there was a
small leftward shift in the generalization curve. This was most evident
at the lowest dose of HC examined (0.5 mg/kg, i.p.), where five of six
animals tested made 75% or more of the total responses on the morphine
appropriate lever, compared to only two of six in nonquinine pretreated
animals (fig. 7).
|
Experiment 5. Effect of CYP2D1 Inhibition on HC
Self-Administration.
In rats trained to lever press for 0.16 mg/kg/infusion HC, alteration of the drug infusion concentration
produced a significant change in the total number of infusions taken
during the 60-min test session (F4,32 = 4.7, P = .004)
(fig. 8). When the dose was reduced, the rats showed a
compensatory increase in the number of infusions taken. Pretreatment
with either quinine (F1,24, = 2.04, NS) or budipine
(F1,24, = 1.0, NS) failed to modify HC self-administration behavior at any of the HC doses over the 1-hr test session (fig. 8).
The accuracy of responding (percentage of lever presses on the active
lever) was approximately 90% throughout the experiment and was not
altered by either different drug infusion doses or by pretreatment with
the CYP2D1 inhibitors.
|
| |
Discussion |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
In humans, variation in the metabolic conversion of HC to HM does
not appear to be related to the opiate effects of HC (Kaplan et
al., 1996). This may be due to the relatively small contribution that this CYP2D6 pathway makes to the overall elimination of this drug.
In EM, clearance of HM accounts for only 4.6% of the total metabolic
clearance of HC (Otton et al., 1993). It is possible that
metabolites formed by other, less variable cytochromes P450 enzymes may
possess opiate-like activity or that the parent compound itself, has
sufficient opiate properties such that the formation of HM is not
essential for the pharmacological activity of HC. Earlier studies have
shown that rats do not N-demethylate HC, and that the major metabolic
reaction is HM formation (Cone and Darwin, 1978). Therefore, it
appeared that the rat was a better model in which to assess the extent
that HM contributes to the analgesic and behavioral effects of HC. This
was examined in our study by establishing animal counterparts of human
PM and EM phenotypes by comparing the effects of HC in the same rat
strain, with or without previous administration of a CYP2D1 inhibitor.
This approach was used previously to demonstrate differences in the
behavioral effects of another CYP2D1 substrate, amphetamine (D. M. Tomkins, unpublished data).
Initially, we confirmed that CYP2D1 inhibition did indeed inhibit the
conversion of HC to HM. Pretreatment with either quinine or budipine
decreased plasma levels of free HM by approximately 70% and was
associated with a complete absence of detectable levels of HM in whole
brain (fig.1). In contrast to the marked effects of CYP2D1 inhibition
on HC metabolism, there were at best, only subtle changes, in the
pharmacological effects of HC after this type of manipulation. At the
doses used, neither budipine, nor quinine, altered the dose response
curve for the antinociceptive effects of HC (fig .2). Because
HC-induced analgesia was reversed by the opioid antagonist, naloxone,
it is doubtful that impaired performance in this task due to repeated
testing on the hot plate would account for these negative findings.
Cleary et al. (1994), have recently shown that CYP2D1
inhibition also failed to alter the analgesic effects of oxycodone,
despite blocking its conversion to oxymorphone, a metabolite with
greater affinity for opioid mu receptors. They raised three
potential explanations for these findings. First, they suggested that
because complete inhibition of CYP2D1 activity was not achieved, enough
of the more active metabolite was formed to produce an analgesic
effect. This would be an unlikely explanation of our HC data because
budipine and quinine, at the doses used, reduced plasma concentrations
of free HM by approximately 70%. The plasma HM levels in the CYP2D1
inhibited animals are considerably lower than the plasma HM levels
achieved after administration of a dose of HM known to elicit similar
antinociceptive effects (on comparison of ED50 for the
analgesic effect of HM from Hennies et al., 1988 and Plummer
et al., 1990, with our pharmacokinetic data following
administration of 0.5 mg/kg HM shown in table 2). Furthermore, this
does not account for the observation that the antinociceptive effects
of lower doses of HC were not altered, despite the fact that one would
predict in this construct that the analgesic effects elicited by
threshold doses of HC would be more susceptible to CYP2D1 inhibition. A
second explanation offered for the oxycodone data (Cleary et
al., 1994) was that inhibition of CYP2D1 activity results in
increased levels of the parent compound of sufficient order of
magnitude to compensate for reduced formation of the more active
product. Again, our pharmacokinetic data suggest this to be unlikely in
the case of HC, because both quinine and budipine failed to alter
HC-induced analgesia, whereas only budipine produced a significant
increase in plasma and brain levels of HC. Furthermore, it is unlikely
that the increased levels of HC observed in budipine pretreated animals
is sufficient to compensate for the more pronounced reductions in HM
levels, particularly when the differences in their affinities for the
mu-opioid receptors is taken into consideration (Hennies
et al., 1988; Chen et al., 1991). A final
explanation, which at present cannot be ruled out, is that an
alternative metabolite is formed that exhibits potent analgesic
effects. However, what these data do demonstrate is that
O-demethylation is not an essential step to produce an analgesic response to HC.
It is evident from the pharmacokinetic data that quinine and budipine
differ moderately in their effects on the metabolism of HC as outlined
above. In terms of their mechanism of action, both quinine and budipine
have been shown to be potent inhibitors of rat CYP2D1 activity (Otton
et al., 1984; Kobayashi et al., 1989; present
study). Quinine's inhibitory activity may be mediated, at least in
part, by an interaction with the ferric form of the CYP 2D1 enzyme
(Murray, 1984), rather than simply acting as a competitive substrate of
this enzyme (Guengerich et al., 1986). In contrast, although
budipine's interaction with the CYP has not been extensively examined,
its potent inhibition of [3H]GBR-12935 binding to CYP2D1
suggests that it is a competitive substrate (Niznik et al.,
1990). However, because both compounds are potent inhibitors of CYP2D1
activity, it would seem unlikely that these different mechanisms of
action at the CYP2D1 enzyme would account for the differences reported
here. Alternatively, because HC is metabolized via a number of
different pathways (Cone and Darwin, 1978), it is possible that
budipine, but not quinine, may also inhibit one or more of these
alternative metabolic routes leading to an accumulation of the parent
compound.
Locomotor activity, drug discrimination and drug self-administration
studies are animal models used to predict the abuse liability of drugs
in humans with relatively good success. In both the drug discrimination
and self-administration studies, CYP2D1 inhibition did not attenuate
the behavioral effects of HC. These data do not correlate with the
human study reported by Otton et al. (1993), in which CYP2D6
inhibition did alter subjective reports of "good drug" effects
during the first hour after administration. One possible explanation
that may account for these discrepant findings is that if the central
metabolism of HC plays a major role in regulating these behaviors, then
the failure of quinine and budipine to modify these behaviors may be
due to an inability to block central metabolism. This has been proposed
previously, because it is known that the diastereoisomer quinidine does
not penetrate the blood brain barrier at doses similar to quinine (Agon
et al., 1988). However, this explanation seems improbable
because our in vivo pharmacokinetic studies clearly show
that brain levels of HM are markedly reduced after CYP2D1 inhibition
(fig. 1). In line with the results of the analgesia studies, these data
suggest that HC has significant pharmacological properties in its own right and does not require conversion to HM. This is further supported in the drug discrimination procedure by the observation that the generalization curves for HC in morphine trained rats were
superimposable at both 30 and 60 min pretreatment, meanwhile, plasma
levels of HM increased 100% between these two time points (table 2).
New evidence supporting the fact that HC exhibits greater opioid
agonist activity than previously thought is now coming to light (France et al., 1995).
In summary, although we have demonstrated that inhibition of CYP2D1 activity in male Wistar rats has a pronounced effect on the pharmacokinetic profile of HC and its biotransformation to the more active metabolite, HM, we found little evidence that this has a significant impact on the pharmacological and behavioral effects of the parent drug. Because inhibition of CYP2D1 in this rat strain is proposed to be a useful animal counterpart for studying the impact of CYP2D6 polymorphism in humans, these data suggest that, differences in CYP2D6 phenotype will have limited, if any, influence on the drug response to HC. Kaplan et al. (1996) have recently verified this, showing that inhibition of HC biotransformation to HM does not affect measures of abuse liability. Therefore, the behavioral effects of HC are most likely attributable to its own intrinsic effects at mu opioid receptors.
| |
Acknowledgments |
|---|
The authors thank Mr. Trevor Berns, Mr. Eric Greenwald, Ms. Ting Chan and Ms. Hua Li for their technical assistance.
| |
Footnotes |
|---|
Accepted for publication November 4, 1996.
Received for publication May 6, 1996.
1 This work was supported by NIDA Grants DA-06889 and DA-01442 and by the Addiction Research Foundation.
Send reprint requests to: Dr. Denise M. Tomkins, Biobehavioral Research Department, Addiction Research Foundation, 33 Russell Street, Toronto, Ontario, M5S S1, Canada.
| |
Abbreviations |
|---|
CYP2D6, cytochrome P450 2D6; CYP2D1, cytochrome P450 2D1; EM, extensive metabolizer; PM, poor metabolizer; HC, hydrocodone; HM, hydromorphone; PLL, paw lick latency; QN, quinine; BUD, budipine; FR, fixed ratio.
| |
References |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
adrenoceptor antagonists and other cardiovascular drugs.
Life Sci.
34: 73-80, 1984[Medline].This article has been cited by other articles:
|
|
 |
|
  S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Peckham and J. R. Traynor Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lalovic, B. Phillips, L. L. Risler, W. Howald, and D. D. Shen QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES Drug Metab. Dispos., April 1, 2004; 32(4): 447 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Thompson, H. Wojno, E. Greiner, E. L. May, K. C. Rice, and D. E. Selley Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at {micro}- and {delta}-Opioid Receptors J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Garrido, O. Sayar, C. Segura, J. Rapado, M. C. Dios-Vieitez, M. J. Renedo, and I. F. Troconiz Pharmacokinetic/Pharmacodynamic Modeling of the Antinociceptive Effects of (+)-Tramadol in the Rat: Role of Cytochrome P450 2D Activity J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 710 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Watanabe, Y. Tarumi, D. Oneschuk, P. Lawlor, R. K. Portenoy, and R. A. Indelicato Opioid Rotation to Methadone: Proceed With Caution J. Clin. Oncol., May 1, 2002; 20(9): 2409 - 2410. [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Williams, D. J. Hatch, and R. F. Howard Codeine phosphate in paediatric medicine Br. J. Anaesth., March 1, 2001; 86(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||
) and budipine (10 mg/kg, 
) on hydrocodone-induced analgesia
(
) assessed using the hot plate test procedure. A comparison with
the effects of the opioid antagonist, naloxone (1 mg/kg, 
);
(n = 8 male Wistar rats).
) on locomotor behavior in male Wistar rats (n = 8 and 7 respectively) during a 2-hr test session. Significant
differences from saline pretreated controls is represented by *P < .01 (Dunnett's t test).
